Smith and Nephew buys rights to Exogen's ultrasound devices:
This article was originally published in Clinica
Exogen has granted Smith & Nephew US exclusive marketing rights to its ultrasound fracture healing devices, with options for S&N to sell the product internationally. S&N will pay $4.1 million for 7% of Exogen's equity as well as an upfront payment of $1 million. The option to distribute internationally is valued at a further $5 million. In addition S&N can add to its shareholding in the Piscataway, New Jersey-based company.